옵션 체인은 다양한 행사가격과 만기일에 대한 CO2 Energy Transition Corp. - Right의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 CO2 Energy Transition Corp. - Right에 대한 시장 심리를 평가합니다..

CO2 Energy Transition Corp. - Right (NASDAQ:NOEMR) 주식, 옵션 체인

CO2 Energy Transition Corp. - Right

Macro Economic Events

News

Econ #s

Economics

"White Smoke Seen Rising From The Vatican"

Keybanc analyst Ken Newman maintains Rockwell Automation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROK#NYSE">ROK</a>) with a Overweight and raises the price target from $275 to $330.

Price Target

Analyst Ratings

Keybanc Maintains Overweight on Rockwell Automation, Raises Price Target to $330

DA Davidson analyst Michael Baker maintains A-Mark Precious Metals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRK#NASDAQ">AMRK</a>) with a Buy and lowers the price target from $35 to $29.

AMRK

DA Davidson Maintains Buy on A-Mark Precious Metals, Lowers Price Target to $29

Keefe, Bruyette &amp; Woods analyst Thomas McJoynt-Griffith maintains Root (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROOT#NASDAQ">ROOT</a>) with a Outperform and raises the price target from $150 to $170.

ROOT

Keefe, Bruyette & Woods Maintains Outperform on Root, Raises Price Target to $170

DA Davidson analyst Kurt Yinger maintains TopBuild (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLD#NYSE">BLD</a>) with a Buy and lowers the price target from $435 to $395.

DA Davidson Maintains Buy on TopBuild, Lowers Price Target to $395

Keefe, Bruyette &amp; Woods analyst Sanjay Sakhrani maintains Payoneer Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAYO#NASDAQ">PAYO</a>) with a Market Perform and lowers the price target from $8 to $7.

PAYO

Keefe, Bruyette & Woods Maintains Market Perform on Payoneer Global, Lowers Price Target to $7

As the drug industry is in the middle of a growing policy maelstrom in Washington, D.C., investors are <a href="https://www.benzinga.com/etfs">closely watching pharmaceutical ETFs</a> to measure market sentiment and ride out the emerging volatility. 
With President Donald Trump&#8217;s administration rehashing contentious ideas on drug pricing and manufacturing policy, the stakes are increasing — not only for Big Pharma, but for the overall healthcare investment environment.
Amid the trends, pharma-targeted ETFs are being watched under a more risk-averse lens. Each of the funds provides sector exposure, but structural idiosyncrasies — and varying levels of protection from regulation-induced shocks — are gaining heightened relevance.
<h1 class="wp-block-heading">Slicing Up The Pharma ETF Scene</h1>
iShares U.S. Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHE#NYSE">IHE</a>)
The ETF offers concentrated exposure to large-cap U.S.-listed pharma companies. Its top holdings are Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), Merck &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), and Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) — companies with strong pipelines and international revenue streams.
Defensive Tilt: IHE&#8217;s emphasis on blue-chip names makes it a relatively defensive play during periods of political unrest.
Policy Sensitivity: But its large weighting in companies with substantial Medicaid and U.S. sales exposure renders it highly sensitive to pharmaceutical pricing reform in the domestic market.
SPDR S&amp;P Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPH#NYSE">XPH</a>)
Unlike IHE, the SPDR S&amp;P Pharmaceuticals ETF uses an equal-weighting style, dispersing exposure across a larger segment of the industry, including mid- and small-cap companies such as Viatris (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTRS#NASDAQ">VTRS</a>).
Diversified Risk: This format caps overconcentration in a single name and increases sensitivity to prospective M&amp;A action.
Higher Volatility: As more importance is assigned to lesser-known participants, XPH can see greater price volatility, particularly as regulatory threats play out.
VanEck Pharmaceutical ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPH#NASDAQ">PPH</a>)
Those in search of global exposure should look at PPH, which includes international powerhouses such as AstraZeneca (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) and Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) on par with U.S. behemoths.
Geopolitical Hedge: International diversification renders PPH less susceptible to U.S.-specific tariff risks or reforms.
Growth Exposure: Novo Nordisk&#8217;s dominance of GLP-1-based obesity treatment provides a high-growth component, although subject to some headwinds due to compounding alternatives in the U.S.
<h1 class="wp-block-heading">Volatility Ahead?</h1>
These ETF dynamics are unfolding against a backdrop of sweeping proposals and heightened industry-government tension. The Trump administration's <a href="https://www.benzinga.com/markets/25/04/44945973/trump-administration-considers-lowering-us-drug-prices-to-international-levels-report">revived push to tether Medicaid drug prices to lower international benchmarks</a> has sent shockwaves through the pharmaceutical sector. Industry analysts estimate the pricing framework could erase as much as $1 trillion in revenue over a decade, according to Bloomberg.
Surprised by the White House&#8217;s latest move, drug industry executives have mounted a concerted lobbying effort, trying to keep the policy from taking hold in Congress. Although some Republican lawmakers, including Kentucky Rep. Brett Guthrie, have reaffirmed their opposition to global reference pricing, the proposal is still a live political threat, Bloomberg reported.
And adding to investor anxiety is Trump&#8217;s latest threat of<a href="https://www.benzinga.com/25/04/44708204/trump-hints-at-major-tariff-on-imported-pharmaceuticals-us-pharma-stocks-tumble-in-wednesday-pre-market"> sector-specific tariffs on drugs</a>. Although the Department of Commerce&#8217;s Section 232 investigation can take months, the threat of new import tariffs — particularly on Indian generics and contract-manufactured products — has already spilled over into related stocks. Insiders within the industry say the administration might move while there is a 90-day moratorium on reciprocal tariff imposition.
Not all of Washington&#8217;s signals are bearish, though. A recently signed executive order is intended to <a href="https://www.benzinga.com/government/regulations/25/05/45215281/trump-orders-fda-to-fast-track-us-drug-production-as-tariff-threat-looms-on-imported-medicines-cites-national-security-concerns">lower FDA approval times for U.S. manufacturing plants</a> — potentially speeding up reshoring and encouraging investment in U.S.-based production. For more exposed domestic manufacturers and smaller company-focused ETFs such as XPH, this may be a long-term tailwind.
<h1 class="wp-block-heading">Proceed, But With Prescription-Strength Caution</h1>
For those looking for exposure to the pharma industry, ETFs are still an important tool — but their variations are more important than ever.
IHE provides stability but is heavily influenced by the success of U.S. policy.
XPH offers balanced exposure and is potentially more sensitive to reforms in domestic manufacturing.
PPH offers a global cushion, especially useful if U.S.-focused risks increase.
In the end, pharma ETFs&#8217; future may depend less on laboratory discoveries than on the political medicine doled out by Washington. 
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/etfs/new-etfs/25/05/45259802/vistashares-launches-qusa-etf-targeting-15-annual-yield-with-quality-us-stocks-options-overlay">VistaShares Launches QUSA ETF, Targeting 15% Annual Yield With Quality U.S. Stocks, Options Overlay</a></li>
</ul>
Photo: Aria Armoko via Shutterstock

Sector ETFs

Health Care

Trading Ideas

ETFs

iShares Dow Jones US Pharmaceuticals Index Fund

Merrill Lynch Pharmaceutical HOLDRs Trust

VTRS

Are Your Health Care ETFs Safe? Trump's New Policies May Trigger Shockwaves Across Pharma Stocks

Keefe, Bruyette &amp; Woods analyst Timothy Switzer maintains NewtekOne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEWT#NASDAQ">NEWT</a>) with a Market Perform and lowers the price target from $15 to $13.

NEWT

Keefe, Bruyette & Woods Maintains Market Perform on NewtekOne, Lowers Price Target to $13

DA Davidson analyst Thomas Diffely maintains Kulicke &amp; Soffa Indus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLIC#NASDAQ">KLIC</a>) with a Buy and lowers the price target from $60 to $55.

KLIC

DA Davidson Maintains Buy on Kulicke & Soffa Indus, Lowers Price Target to $55

WIIM

NXPI

Shares of chip stocks are trading higher following a report indicating President Trump will rescind global chip curbs.

Keefe, Bruyette &amp; Woods analyst Sanjay Sakhrani maintains Marqeta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MQ#NASDAQ">MQ</a>) with a Market Perform and raises the price target from $4 to $4.5.

Keefe, Bruyette & Woods Maintains Market Perform on Marqeta, Raises Price Target to $4.5

A federal judge in Florida has tossed out the bulk of allegations targeting celebrities and social media influencers who endorsed the <a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45226571/ftx-creditors-sold-potential-500m-anysphere-stake-for-200000-before-startups-valuation-tripled">failed cryptocurrency exchange FTX</a>.
What Happened: Among those cleared of most claims are NFL legend Tom Brady, supermodel Gisele Bündchen, investor Kevin O'Leary, and NBA star Stephen Curry, CNBC <a href="https://www.cnbc.com/2025/05/08/ftx-claims-steph-curry-tom-brady-celebrities.html">reported</a>.
The ruling significantly limits a wide-ranging lawsuit filed by FTX investors, who alleged that the stars misled the public by promoting the platform without disclosing multimillion-dollar endorsement deals.
FTX collapsed in November 2022, evaporating billions in customer funds and prompting global investigations into its founder, Sam Bankman-Fried, who was later convicted of fraud.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45248184/bitcoin-is-no-longer-just-digital-gold-native-staking-yield-are-redefining-its-role-says-core-dao">Bitcoin Is No Longer Just Digital Gold — Native Staking, Yield Are Redefining Its Role, Says Core DAO</a>
In the decision filed Wednesday, U.S. District Judge K. Michael Moore found that the plaintiffs had not shown that the so-called "Celebrity Defendants" had adequate knowledge of FTX&#8217;s alleged misconduct to justify legal liability.
The judge also dismissed most claims against several YouTube influencers who were named in the lawsuit for promoting FTX via their channels. 
These influencers, dubbed the "YouTuber Defendants," were similarly accused of failing to disclose financial ties to the exchange.
The decision deals a blow to investor efforts to hold endorsers accountable for the platform's downfall, which centered on accusations of promoting unregistered securities and engaging in deceptive marketing.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45231848/bitcoin-eyes-100000-experts-assert-but-will-the-federal-reserve-play-ball">Bitcoin Eyes $100,000, Experts Assert, But Will The Federal Reserve Play Ball?</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Judge Dismisses Most Claims Against Tom Brady, Stephen Curry Over FTX Crypto Endorsements

Keybanc analyst Alex Markgraff maintains Remitly Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RELY#NASDAQ">RELY</a>) with a Overweight and raises the price target from $24 to $27.

RELY

Keybanc Maintains Overweight on Remitly Global, Raises Price Target to $27

Keefe, Bruyette &amp; Woods analyst Kyle Voigt maintains MarketAxess Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MKTX#NASDAQ">MKTX</a>) with a Market Perform and raises the price target from $223 to $226.

MKTX

Keefe, Bruyette & Woods Maintains Market Perform on MarketAxess Holdings, Raises Price Target to $226

Acquisition expands FirstService Residential's footprint in Edmonton, Alberta, and Western Canada
EDMONTON, AB, May 8, 2025 /CNW/ - <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4422601-1&amp;h=4102104025&amp;u=https%3A%2F%2Fwww.fsresidential.com%2Falberta%2F&amp;a=FirstService+Residential">FirstService Residential</a>&nbsp;announced the acquisition of Edmonton-based Core Real Estate Group.
Core Real Estate Group, serving residential properties in Edmonton since 2011, manages more than 15,000 residential units. The acquisition brings the number of residential units under FirstService management in Canada to more than 250,000, reinforcing FirstService's leadership position in property management in Canada.
 &nbsp;

FirstService Residential Acquires Edmonton-Based Core Real Estate Group; Terms Not Disclosed

Keefe, Bruyette &amp; Woods analyst Bose George maintains MFA Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MFA#NYSE">MFA</a>) with a Outperform and lowers the price target from $12.5 to $12.

Keefe, Bruyette & Woods Maintains Outperform on MFA Finl, Lowers Price Target to $12

CNH's new Strategic Business Plan set to enhance product leadership and expand margins
<ul>
<li>CNH's new Strategic Business Plan will: 
<ul>
<li>Consolidate its position as the #1 or #2 player in all major markets</li>
<li>Target a 16-17% Agriculture mid-cycle adjusted EBIT margin by 2030</li>
<li>Execute an additional $550M+ in run-rate operational and quality cost improvements</li>
<li>Increase through-cycle Industrial cash generation by 25% &nbsp;</li>
</ul>
</li>
<li>Key strategy pillars include: 
<ul>
<li>Advancing Iron + Tech integration. Precision Tech sales will nearly double as a percentage of total Agriculture Net Sales during the plan period</li>
<li>Strengthening our go-to-market approach through a new dual-brand dealer strategy</li>
<li>Relentless focus on end-to-end quality</li>
</ul>
</li>
</ul>
Basildon, May 8, 2025
CNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNH#NYSE">CNH</a>) presented its Strategic Business Plan (SBP) today at the Company's <a href="https://www.globenewswire.com/Tracker?data=Ze_rRWXBZajuwCGWm59Itdlq2kQSxRbXSxcmIAFGPvaBe85tfpQmUonaDPX8ZfGgCpnge7YBqH0YD4oMGdjH6GKr3ZcYj6YaK1k1S7PJ0Kw=">Investor Day 2025</a>.
PATH TO 2030
Chief Executive Officer Gerrit Marx introduced the SBP's core pillars:
<ol>
<li>Breaking New Ground on Iron + Tech</li>
<li>Further expanding mid-cycle adjusted EBIT margins</li>
<li>Forward strategy for Construction</li>
<li>Returning substantially all Industrial Free Cash Flow (FCF) to shareholders through the cycle</li>
</ol>
"The strategy that we presented today shows that we have a clear path to achieve our goals. We are committed to delivering strong growth, in tandem with our cost efficiency targets. We have demonstrated our capability to deliver steady margin improvements in the past, and we will take that to the next level in this new phase of our journey,"&nbsp;said Gerrit Marx, Chief Executive Officer at CNH.
BREAKING NEW GROUND ON IRON + TECH
CNH will consolidate its position as the first or second agriculture player in all major markets during the plan period.&nbsp; &nbsp; We will solidify and strengthen our product leadership across all phases of the agricultural cycle through launches, updates and new features for our tractors, harvesters, crop production and crop protection equipment. CNH already offers the industry's most advanced and sophisticated combine harvesters, and we will further expand our harvesting lineup to maintain our leading position. Our new generation twin and single rotor combines launched in 2024 are delivering for farmers with a 15% lower total cost of ownership. A full refresh of our tractor lineup covering the 20 to 700+ horsepower model range is underway, and from 2026 onwards, we will continue to progressively introduce new product lines.&nbsp;
Thanks to our investments in technology, and by adopting and embedding advanced Artificial Intelligence (AI) capabilities, we are creating the best user experience for customers through the seamless integration of our Precision Tech into our equipment (Iron). Our Precision Tech offering includes agronomic sensors, smart implements, advanced automation, autonomous features, satellite connectivity, agronomic insights, and machine data synchronization via our FieldOps&#x2122; digital platform.
We are installing our Precision Tech systems as factory-fit across all major product lines, as well as focusing on increasing integration across all products. By 2030, 90% of these systems will be developed in-house. By the end of the plan period, the contribution of Precision Tech sales will nearly double as a percentage of total Agriculture Net Sales, driving additional margin.
A new go-to-market strategy centered on an integrated and regionally tailored dealer network and brand strategy will see CNH drive higher farmer engagement with greater focus on better and faster customer service. We will leverage and balance our existing global network, which is industry-leading in terms of customer proximity with ~6,000 points of sale and service. Central to our strategy is the strengthening of our brands' identities: Case IH and New Holland as global brands and STEYR as a dedicated European brand, each serving distinct customer segments.
Crucial to this strategy is the establishment of a ‘New Deal' with our dealers, which will see us invest ~100 bps of annual margin over the next five years in growth-oriented dealers. We are also investing in enhancing customer-centric service capabilities through integrated platforms and AI-powered solutions for programmed and predictive maintenance, increased connectivity for units, and retrofit solutions to deliver a seamless customer and dealer experience that targets 100% uptime and a ‘fix right the first time' guarantee.
FURTHER EXPANDING MID-CYCLE EBIT MARGINS&nbsp;
CNH is targeting a 16-17% Agriculture mid-cycle adjusted EBIT margin by 2030. This ambition will be achieved through a combination of margin expansion initiatives tied to commercial growth, operational efficiency, and quality improvements.
Specifically, CNH expects to generate margin expansion through commercial growth initiatives that consist of Precision Tech product mix and go-to-market actions; operational efficiencies relating to strategic sourcing, plant efficiencies, and our manufacturing footprint; and quality enhancements driven by greater product reliability, advanced manufacturing processes, and stronger dealer partnerships. We are committed to delivering in excess of $550 million in operational and quality cost improvements by 2030 to support this margin expansion.
For Construction, we are targeting a 7-8% mid-cycle adjusted EBIT margin by 2030. We will specifically generate this margin expansion via commercial actions, sourcing improvements, and manufacturing improvements.&nbsp;
We are committed to deliver increasing value to our shareholders. We will increase through-cycle Industrial cash generation by 25%, enabling higher returns to shareholders. After debt repayment and M&amp;A opportunities, we plan to return substantially all Industrial FCF to shareholders through a consistent dividend (25-35% of net income) and share buybacks through the industry cycle.
 &nbsp;

CNH Targets 16%-17% Agriculture Mid-Cycle Adjusted EBIT Margin By 2030

Lucid Group, Inc.&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>) share price rose modestly on Thursday, buoyed by the unveiling of a new location aimed at enhancing customer <a href="https://www.benzinga.com/pressreleases/25/05/n45284976/lucid-opens-new-jersey-studio-service-and-delivery-center-for-area-customers" target="_blank" rel="noreferrer noopener">support in the Tri-State region.</a>
The electric vehicle company, recognized for its premium performance and design, launched a new Studio and Service Center in Rutherford, New Jersey.
This latest addition brings Lucid&#8217;s total to 43 physical locations across North America and 58 globally.
Check This Out:&nbsp;<a target="_blank" href="https://www.benzinga.com/25/05/45245613/rivian-ceo-rj-scaringe-says-donald-trumps-tariffs-could-increase-costs-by-a-couple-of-thousand-as-company-slashes-delivery-projections" rel="noreferrer noopener">Rivian CEO RJ Scaringe Says Donald Trump&#8217;s Tariffs Could Increase Costs By &#8216;A Couple Of Thousand,&#8217; Slashes Delivery Projections</a>
Erwin Raphael, vice president of revenue at Lucid, stated that the brand is gaining popularity among drivers in the Garden State. &#8220;Our passionate Lucid team members are eager to welcome new and prospective customers and deliver the outstanding experience that our owners have come to expect from Lucid,&#8221; Raphael said in a statement.
The Rutherford facility is positioned to serve a rapidly expanding customer base.
The move deepens Lucid&#8217;s footprint in the Tri-State region, complementing existing locations in Short Hills, White Plains, Manhattan, Plainview, Manhasset and King of Prussia.
The EV maker recently posted $235.05 million in first-quarter revenue, slightly <a target="_blank" href="https://www.benzinga.com/news/earnings/25/05/45260168/whats-going-on-with-ev-stocks-rivian-lucid-on-wednesday" rel="noreferrer noopener">missing analysts&#8217; forecasts of $250 million.</a>
However, it narrowed its net loss to 20 cents per share, beating expectations of a 23-cent loss.
In the same period, Lucid delivered 3,109 vehicles while producing 2,212. The production tally does not include over 600 units en route to Saudi Arabia.
The company remains committed to its annual production guidance of approximately 20,000 vehicles in 2025.
Price Action: LCID shares are trading higher by 0.89% to $2.270 at last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/05/45234350/duolingo-analyst-sees-ebitda-expansion-strong-user-trends-and-monetization-upside" target="_blank" rel="noreferrer noopener">Duolingo Scores High Marks From JPMorgan As Learners, Profits Multiply</a></li>
</ul>
Photo: Shutterstock

Equities

Markets

Movers

General

LCID

What's Going On With Lucid Group Stock Today?

Keefe, Bruyette &amp; Woods analyst Sanjay Sakhrani maintains Jack Henry &amp; Associates (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JKHY#NASDAQ">JKHY</a>) with a Market Perform and lowers the price target from $190 to $183.

JKHY

Keefe, Bruyette & Woods Maintains Market Perform on Jack Henry & Associates, Lowers Price Target to $183

In the current market session, Madison Square Garden Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSGE#NYSE">MSGE</a>) share price is at $36.09, after a 0.69% drop. Over the past month, the stock went up by 18.95%, but over the past year, it actually decreased by 3.01%. With good short-term performance like this, and questionable long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio.

<img src="https://www.benzinga.com/files/images/story/2025/1746720094_0.png" alt="Past Year Chart" />

<h3>A Look at Madison Square Garden P/E Relative to Its Competitors</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Madison Square Garden has a lower P/E than the aggregate P/E of 972.28 of the Entertainment industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1746720094_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Comments

CO2 Energy Transition Corp. - Right

CO2 Energy Transition Corp. - Right (NOEMR) 옵션

No option chain data available. Please try again later

뉴스

파트너 / 기고자

벤징가 글로벌